68,927 Shares in Wave Life Sciences Ltd. (NASDAQ:WVE) Purchased by Quantbot Technologies LP

Quantbot Technologies LP purchased a new stake in Wave Life Sciences Ltd. (NASDAQ:WVE) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 68,927 shares of the company’s stock, valued at approximately $853,000.

Several other large investors also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its position in shares of Wave Life Sciences by 209.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 844,617 shares of the company’s stock worth $6,926,000 after purchasing an additional 571,345 shares during the period. FMR LLC increased its stake in Wave Life Sciences by 174.5% in the 3rd quarter. FMR LLC now owns 1,540,190 shares of the company’s stock worth $12,630,000 after purchasing an additional 979,110 shares in the last quarter. Maven Securities LTD purchased a new position in Wave Life Sciences in the 3rd quarter worth about $6,970,000. Barclays PLC lifted its stake in Wave Life Sciences by 171.1% during the third quarter. Barclays PLC now owns 159,241 shares of the company’s stock valued at $1,307,000 after buying an additional 100,498 shares in the last quarter. Finally, Cinctive Capital Management LP boosted its holdings in shares of Wave Life Sciences by 255.7% in the third quarter. Cinctive Capital Management LP now owns 356,308 shares of the company’s stock worth $2,922,000 after buying an additional 256,146 shares during the period. Institutional investors own 89.73% of the company’s stock.

Wave Life Sciences Trading Up 6.1 %

Shares of NASDAQ:WVE opened at $10.02 on Thursday. The business has a fifty day simple moving average of $10.83 and a 200 day simple moving average of $11.64. Wave Life Sciences Ltd. has a 1 year low of $4.25 and a 1 year high of $16.74. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -9.03 and a beta of -1.04.

Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million during the quarter, compared to analyst estimates of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. On average, sell-side analysts forecast that Wave Life Sciences Ltd. will post -1.14 EPS for the current year.

Insider Buying and Selling at Wave Life Sciences

In related news, CEO Paul Bolno sold 169,025 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the transaction, the chief executive officer now directly owns 338,351 shares of the company’s stock, valued at approximately $3,238,019.07. This trade represents a 33.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christian O. Henry sold 10,500 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total value of $102,585.00. Following the sale, the director now directly owns 16,115 shares of the company’s stock, valued at $157,443.55. The trade was a 39.45 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 29.10% of the company’s stock.

Analyst Upgrades and Downgrades

WVE has been the topic of a number of recent analyst reports. Jefferies Financial Group assumed coverage on shares of Wave Life Sciences in a report on Tuesday, February 25th. They set a “buy” rating and a $26.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of Wave Life Sciences in a research note on Wednesday. Finally, StockNews.com raised Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 8th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Wave Life Sciences currently has an average rating of “Moderate Buy” and an average price target of $22.60.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.